Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | CCR3 | P51677 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304204 | 0.92 | FAAH (0.48) | KMT2AMEN1CYP2D6CYP2C19LMNA | |
| SCHEMBL6304207 | 0.92 | FAAH (0.48) | KMT2AMEN1CYP2D6CYP2C19LMNA | |
| SCHEMBL6312019 | 0.88 | CCR3 (0.56) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6312016 | 0.88 | CCR3 (0.56) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6303831 | 0.85 | POLB (0.44) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6303829 | 0.85 | POLB (0.44) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6303723 | 0.85 | SMN1; SMN2 (0.46) | KMT2AMEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6303726 | 0.85 | SMN1; SMN2 (0.46) | KMT2AMEN1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6303713 | 0.83 | KMT2A (0.46) | KMT2AMEN1LMNACCR3MAPT | |
| SCHEMBL6303712 | 0.83 | KMT2A (0.46) | KMT2AMEN1LMNACCR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | KMT2A 3093/4885MEN1 4556/4885CYP1A2 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.